The Cancer Cell Biology Research Group attended EACR-MRS Joint Conference titled «Seed and Soil: In Vivo Models of Metastasis», a virtual event held on 25-26 January 2022. A few months later, 20-23 June 2022, lab members Cristina Benítez-García and Dr. Pere Fontova were part of EACR 2022 Annual Congress in Seville (Spain), in which they[…]

Dr. Pere Fontova has joined the Cancer Cell Biology Research Group as a postdoctoral researcher and collaborator from the Bioorganics Chemistry Group at University of Burgos. There, he is involved in studying the cellular and molecular mechanism, as well as their effectiveness in different cancer models, of different anionophore experimental compounds for cancer treatment. Welcome[…]

Despite of the COVID-19 pandemic, the Cancer Cell Biology Research Group participated in the virtual meetings of 17th ASEICA International Congress, AACR Virtual Annual Meeting and EACR Virtual Congress in 2020.

In collaboration with Dr. Roberto Quesada research group at University of Burgos, we have published a research paper about click-tambjamines, a novel class of transmembrane anion carriers which display remarkable anionophoric activities in model liposomes and living cells. The versatility of this building block for the generation of molecular diversity offers promise to develop future[…]

We will participate in a challenging project aimed at nanoencapsulating experimental and currently used chemotherapeutics for lung cancer treatment in collaboration with  Ecopol Tech Company, which has been awarded a  «Nuclis» Grant from the Catalonian Government.  

We have recently published a compilation of therapeutic strategies that modulate autophagy for the treatment of cancer and tumor chemosensitization in Cancers Journal (Q1 Oncology).   Title: Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization Authors: Marta Pérez-Hernández, Alain Arias, David Martínez-García, Ricardo Pérez-Tomás, Roberto Quesada and Vanessa Soto-Cerrato. Abstract: Abstract: Autophagy is a tightly[…]

We have published a new paper in Biomolecules Journal elucidating the molecular mechanism by which an anticancer compound exerts survivin inhibition in different lung cancer models.   Title: The Natural-Based Antitumor Compound T21 Decreases Survivin Levels through Potent STAT3 Inhibition in Lung Cancer Models Authors: David Martínez-García, Marta Pérez-Hernández, Luís Korrodi-Gregório, Roberto Quesada, Ricard Ramos,[…]

We have recently published, in Medicinal Research Reviews, a paper about  survivin protein in cancer. In this review,  therapeutic options targeting survivin for cancer treatment are analyzed. Direct survivin inhibitors and their current development status are explored. Moreover, the major signaling pathways implicated in survivin regulation are described and different therapeutic approaches involving survivin indirect inhibition are evaluated. Finally, promising novel[…]

We want to welcome Dr. Marta Pérez-Hernández, who has recently joined the Cancer Cell Biology Group as a PostDoctoral researcher and has a strong background in both Cancer and Nanomedicine fields.  

A new grant from the Spanish government has been awarded to PIs Dr. Ricardo Pérez-Tomás and Dr. Vanessa Soto-Cerrato for the therapeutic preclinical evaluation of new survivin inhibitors for cancer treatment.